Alex C. Sapir

Alex Sapir serves as the Chief Executive Officer at Fulcrum Therapeutics since June 2023. Prior to this role, Alex was a Faculty Lecturer at The Wharton School for the first half of 2023 and an Independent Board Member at PhaseBio Pharmaceuticals, Inc. from February 2020 to March 2023. As Chief Executive Officer of ReViral Ltd. from June 2019 to July 2022, Alex led a clinical-stage company focused on antiviral compounds for respiratory syncytial virus. Previously, as President and CEO of Dova Pharmaceuticals from December 2016 to March 2019, Alex oversaw the company's growth through a successful IPO, transitioning it into a fully-integrated biotech firm. Alex's earlier experience includes roles as Executive Vice President at United Therapeutics, Senior Director at Guilford Pharmaceuticals, Consultant at ZS Associates, and various positions at GSK. Alex holds an MBA in Finance and Strategy from Harvard Business School and a BA in Economics from Franklin & Marshall College.